Retifanlimab
Anal Canal Squamous Cell Carcinoma
Explore 8 assets in Anal Canal Squamous Cell Carcinoma →Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Incyte Corporation
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04580485CT.gov INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | — | Completed | — | — | — |
NCT04472429CT.gov Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). | — | Completed | — | — | — |
NCT06910137CT.gov An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC) | — | Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Anal Canal Squamous Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Retifanlimab (this asset) | Incyte Corporation | P3 | BB · 66 |
| Carboplatin | Incyte Corporation | P3 | BB |
| Nivolumab | National Cancer Institute (NCI) | P3 | BB |
| Fluorouracilum | National Cancer Institute (NCI) | P2 | B |
| Cis-Diamminedichloroplatinum Ii | M.D. Anderson Cancer Center | P2 | B |
| Ipilimumab | National Cancer Institute (NCI) | P2 | CCC |
| Capecitabine | National Cancer Institute (NCI) | P2 | CCC |
| Fludeoxyglucose | National Cancer Institute (NCI) | P2 | CCC |
| Muamycin | National Cancer Institute (NCI) | P2 | CCC |
+3 more in the Anal Canal Squamous Cell Carcinoma cohort
Other indications for Retifanlimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Urothelial Carcinoma | — | P2 | BB · 66 |
| Renal Cell Carcinoma | — | P2 | B · 63 |
| Non-Small Cell Squamous Lung Carcinoma | — | P3 | B · 63 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Retifanlimab in Anal Canal Squamous Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/retifanlimab-anal-canal-squamous-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →